ClinicalTrials.gg
RecruitingNCT07624513Updated Oct 9, 2026

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

A Phase 3 interventional study of Isatuximab and Iberdomide in Multiple Myeloma, sponsored by Dana-Farber Cancer Institute. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Dana-Farber Cancer Institute · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 9, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
720
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing isatuximab in Multiple Myeloma — 15 open to participants now, 34 under way, 9 of them phase 3. isatuximab · Multiple Myeloma.

Planned enrollment
2nd of 50
720 · median 55
Started
2026
with 2 others
Phase 3
9 of 50
1 open now
Primary completion
2033-10
later than 33 of 33 live
Registered
49th of 50
by date
Lead sponsor
2 of 50
Dana-Farber Cancer Institute

Among the 50 studies testing isatuximab in Multiple Myeloma, this one is the 2nd largest by planned enrollment, is one of 3 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 33 of the 33 other live ones, and was the 49th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 50 studies testing isatuximab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About isatuximab

isatuximab: first FDA approval 2020 (SARCLISA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing isatuximab in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment. This is a randomized research study evaluating treatment for transplant-eligible participants with newly diagnosed multiple myeloma (NDMM). Induction therapy in this study includes the drugs isatuximab, iberdomide, bortezomib, and dexamethasone. After induction therapy, participants will receive consolidation and maintenance therapy that is adapted based on their risk profile and response to treatment.

The research study procedures include: screening for eligibility, study visits, blood and bone marrow tests, disease assessments, treatment with study drugs, and follow-up visits.

It is expected that about 720 participants will take part in this study.

Read the detailed description

This is a Phase III, open-label, multicenter randomized research study designed to evaluate different treatment strategies for people with multiple myeloma. The study will look at how often participants achieve MRD (measurable residual disease)-negative status after maintenance therapy, compare different consolidation approaches, and assess long-term outcomes. Participants who are eligible will be assigned to study groups based on their cytogenetic risk and how their disease responds to induction therapy.

All participants will first receive induction treatment with isatuximab, iberdomide, bortezomib, and dexamethasone for 8 cycles. After induction, participants with standard-risk disease who are MRD-negative will continue to maintenance treatment with isatuximab and iberdomide for up to 36 cycles. After that, depending on their MRD status, they may continue on iberdomide alone or remain on the combination treatment. Participants with high-risk cytogenetics and those who remain MRD-positive after completion of induction will be randomized to receive either high-dose melphalan followed by autologous stem cell transplant or eight cycles of linvoseltamab consolidation, followed by maintenance isatuximab and iberdomide until progression of disease. Participants who are deemed medically ineligible for HDM-ASCT (after enrollment but before randomization) and those with indeterminate MRD status after induction may receive maintenance treatment with isatuximab, iberdomide, and bortezomib in lieu of randomization. The study also includes biomarker testing and participant-reported outcome assessments.

The research study procedures include screening for eligibility, clinic visits, blood tests, urine tests, computed tomography (CT) scans, bone marrow sample collection and biobanking, MRD testing, stem cell collection, skeletal survey or positive emission tomography (PET) scans, and electrocardiograms.

The study drugs include melphalan, bortezomib, isatuximab, and dexamethasone, which are approved by the FDA for the initial treatment of multiple myeloma. Linvoseltamab is approved by the FDA for multiple myeloma that has returned after at least four prior lines of treatment. Iberdomide is approved by the FDA for multiple myeloma that has returned after at least one prior line of treatment.

The study also includes an injector device, referred to as the On Body Delivery System (OBDS), also called Isatuximab subcutaneous Wearable Injection System. OBDS is a sterile, single-use, disposable, elastomeric, user-filled medical device, which includes an on-body delivery device designed for subcutaneous delivery of a defined volume of drug product and an integrated drug product syringe transfer base.

It is expected that about 720 people will take part in this research study.

Sanofi Pharmaceuticals, is supporting this research study by providing isatuximab, Celgene, a subsidiary of Bristol-Myers Squibb, is providing, iberdomide, and Regeneron is providing linvoseltamab. Study drugs are free of charge and all sponsors are providing some funding for the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • N- NDMM based on IMWG criteria with clonal bone marrow plasma cells ≥10% or proven bony or extramedullary disease/plasmacytoma (EMD) with any one or more CRAB-features or myeloma defining events (Rajkumar, 2024) (See Appendix E)
  • - Age 18 - 75 years. (Patients aged 71-75 years who are deemed transplant-eligible by investigator may be enrolled after discussion with and approval from the Sponsor - Investigator)
  • - Eligible for HDM-, at time of registration per investigator's assessment, and willing to defer HDM-ASCT if in Cohort 1 or be randomized to HDM-ASCT vs. linvoseltamab if in Cohort 2 (Cohort assignment may not be known until after induction therapy)
  • - Bone marrow analysis with cytogenetic risk status established by fluorescence in situ hybridization (FISH) and NGS with TP53 by PlasmaSEQ at screening and positive identification of B-cell Clonality (ID) conducted by Adaptive Biotechnologies clonoSEQ® assay

    • Qualified archival BMA may be submitted to Adaptive Biotechnologies clonoSEQ® assay.
    • Results from a previously performed clonoSEQ® assay as standard of care may be acceptable if they meet the requirement of B-cell clonality ID.
    • Previously performed BMA for FISH is acceptable if it can establish cytogenetic risk per Section 5.4.2 along with NGS for TP53 by PlasmaSEQ.
    • Results must be within 1 year of screening and be representative of current NDMM. Results older than one year must be approved by the Sponsor-Investigator.
  • defined by at least one of the following:

    • Serum protein electrophoresis (SPEP): Serum M protein ≥0.5 mg/dL
    • Urine protein electrophoresis (UPEP): Urine M protein ≥200 mg/24 hours
    • Serum free light chain (FLC) assay: involved FLC ≥10 mg/dL (≥100 mg/L) and abnormal serum FLC ratio (\<0.26 or >1.65)
  • Screening laboratory evaluations meeting the following parameters:

    • (ANC) ≥1,000 cells/dL (1.0 × 10\^9/L). Growth factor support is not permitted within 10 days [14 days for pegfilgrastim], prior to registration
    • count ≥ 75,000 cells/dL (75 x 109/L) without transfusions required during the 14 days prior to registration
    • Total ≤ 2 X (ULN) (except patients with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL)
    • (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT) ≤ 3.0 x ULN
    • Calculated ≥30 mL/min (See Appendix B)
    • ≥ 8.0 g/dl (red blood cell [RBC] transfusions are permitted)
  • (ECOG) performance status ≤2 (see Appendix A)
  • Ability and willingness to complete HRQoL and PRO-® assessments
  • Must be able to take antithrombotic prophylaxis
  • Sexually active IOCBP agree to use protocol-specified methods, at least 28 days prior to starting study drug, while taking study drug, including interruptions in study drugs, and for at least 28 days after the last dose of iberdomide, 5 months after isatuximab, 6 months after linvoseltamab and bortezomib, or males (including those who have had a vasectomy), sexually active with IOCBP, agree to use protocol specified contraceptive methods while taking study drug, including interruptions in study drug and for at least 28 days after the last dose of iberdomide, 5 months after isatuximab, 6 months after linvoseltamab and bortezomib according the PPP (See Appendix G)
  • All patients (male and female with or without ) agree to counseling according to the PPP and to abstain from donating blood products for at least 28 days after the last dose of iberdomide and semen or sperm while taking study drug and for at least 28 days after the last dose of iberdomide according to the PPP (See Appendix G) and for 3 months after the last dose of isatuximab, 6 months after the last dose of linvoseltamab and bortezomib
  • Both men and women of all races and ethnic groups are eligible for this trial.

Exclusion criteria

Exclusion Criteria:

  • Prior therapy for MM. Patients may have received:

    • for management of MM not exceeding the equivalent of 160 mg of dexamethasone in a 2-week period and without change in dosing requirements within 7 days prior to registration
    • Focal palliative radiation for the management of bone pain ≥ 7 days prior to registration
    • Treatment for smoldering multiple myeloma (SMM) if the prior treatment was not an anti-CD38 or anti-BCMA-based therapy:
    • Patients with a prior history of serious allergic reactions associated with thalidomide, lenalidomide, or pomalidomide should not receive iberdomide as they could be at higher risk of
    • Resolution of symptoms of prior treatment to ≤ grade 1or baseline
  • Known intolerance to steroid therapy
  • Central nervous system (CNS) involvement of MM
  • History of progressive multifocal leukoencephalopathy (PML), known or suspected PML, or history of a neurocognitive condition, CNS movement disorder, history of seizure within 12 months prior to enrollment
  • Peripheral neuropathy grade ≥3, or grade 2 with pain on clinical exam during screening period
  • Prior history of , other than MM, will be excluded unless the participant has been free of the disease for ≥ 3 years, except for the following non-invasive malignancies: basal or squamous cell skin carcinoma, carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histological findings of prostate cancer (T1a or T1b using the TNM clinical staging system), or prostate cancer that is curative
  • Any medical or psychiatric illness that in the investigator's opinion would impose excessive risk or would adversely affect patient participation
  • Concurrent uncontrolled cardiovascular conditions (uncontrolled hypertension [HTN], uncontrolled arrhythmias, congestive heart failure [CHF], unstable angina, grade 3 thromboembolic event or myocardial infarction in the past 6 months)
  • Concurrent symptomatic amyloidosis or plasma cell leukemia
  • POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes)
  • Pregnant or breast feeding female or female who intends to become pregnant during the study
  • Seropositive for (HIV-1), chronic or active (defined as positive hepatitis B surface antigen [HepBSAg] or Hepatitis B core antibody [HepBcore Ab]) or (Hep C Ab), or acute hepatitis A; if any history of exposure to hepatitis B or C, then PCR should be negative
  • History of tuberculosis or systemic fungal disease
  • Concurrent active infection requiring therapeutic treatment
  • Lack of clonal identification by Adaptive Biotechnologies clonoSEQ® test
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
720 participants (estimated)

Study arms

  • Other
    Arm A (Induction and screening)

    All enrolled participants begin with Step 1 induction that consists of eight 28-day cycles before end-of-induction cohort assignment. Peripheral Blood Stem Cells (PBSC) mobilization/collection is planned after completion of 4-6 cycles of induction for participants without disease progression. End-of-induction MRD/response and cytogenetic risk status determine whether participants proceed to post-induction Cohort 1 or Cohort 2.

    Drug: Isatuximab · Drug: Iberdomide · Drug: Bortezomib (B) · Drug: Dexamethasone · Device: On Body Delivery System (OBDS)

  • Other
    Arm B (Cohort 1 Maintenance Therapy Part 1)

    Participants assigned to Cohort 1 enter Arm B and receive isatuximab + iberdomide maintenance for 36 cycles. Maintenance should begin within 28 days of the last induction cycle.

    Drug: Isatuximab · Drug: Iberdomide · Device: On Body Delivery System (OBDS)

  • Other
    Arm C: Cohort 1 Maintenance Therapy (Part 2), Single-Agent Iberdomide

    After completion of Arm B, participants with MRD-negative Complete Response (CR) status at Step 3 are assigned to Arm C and continue single-agent iberdomide until progression. Isatuximab is not administered in Arm C.

    Drug: Iberdomide

  • Other
    Arm D: Cohort 1 Maintenance Therapy (Part 2), Iberdomide + Isatuximab

    After completion of Arm B, participants with MRD-positive or MRD-indeterminate disease, or \<VGPR (very good partial response) at Step 3 evaluation \[unless Progressive Disease (PD)\], continue iberdomide + isatuximab until progression.

    Drug: Isatuximab · Drug: Iberdomide · Device: On Body Delivery System (OBDS)

  • Active comparator
    Arm E: Cohort 2 Randomized Consolidation and Maintenance (HDM-ASCT) Strategy

    Eligible Cohort 2 participants are randomized to Arm E: High-Dose Melphalan followed by Autologous Stem Cell Transplantation (HDM-ASCT) consolidation followed by isatuximab + iberdomide maintenance until progression. The protocol identifies Arm E as the control arm and describes HDM-ASCT-based therapy as the SOC comparator for Cohort 2. Consolidation should begin preferably within 30 days, and no later than 42 days, after induction completion. Maintenance begins 60-110 days after PBSC infusion.

    Drug: Isatuximab · Drug: Iberdomide · Drug: Melphalan · Device: On Body Delivery System (OBDS)

  • Experimental
    Arm F: Cohort 2 Randomized Consolidation and Maintenance (Linvoseltamab Strategy)

    Eligible Cohort 2 participants are randomized to Arm F: linvoseltamab consolidation for 8 cycles followed by isatuximab + iberdomide maintenance until progression. The protocol explicitly identifies Arm F as the experimental arm and hypothesizes superior efficacy versus Arm E. Maintenance should begin within 2-4 weeks after the last linvoseltamab dose.

    Drug: Isatuximab · Drug: Iberdomide · Drug: Linvoseltamab · Device: On Body Delivery System (OBDS)

  • Other
    Arm G: Cohort 2 Non-randomized 3-Drug Maintenance

    Participants in Cohort 2 who do not meet criteria for consolidation therapy may enter Arm G. Standard Risk (SR) MRD-indeterminate participants may also enter Arm G or, with Sponsor-Investigator approval, may be randomized in Cohort 2. Arm G is a 3-drug maintenance regimen continued in 28-day cycles until progression. The protocol explicitly states that dexamethasone is excluded from Arm G.

    Drug: Isatuximab · Drug: Iberdomide · Drug: Bortezomib (B) · Device: On Body Delivery System (OBDS)

Interventions

  • Supplied by Sanofi-Aventis (Sanofi); used in induction and maintenance/consolidation strategies in this protocol; administered subcutaneously (SC) in the maintenance tables provided; not administered in Arm C.

    Also known as: Sarclisa

  • Supplied by Bristol Myers Squibb/Celgene (BMS); used across induction and maintenance phases; administered orally.

    Also known as: CC-220

  • DrugBortezomibStudies of BortezomibBortezomib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Commercial supply; used in induction and Arm G maintenance; administered subcutaneously in Arm G on Days 1 and 15 of each 28-day cycle.

    Also known as: BORT

  • Commercial supply; used in induction; may be administered intravenously or orally at investigator discretion; excluded from Arm G.

  • Commercial supply; used as conditioning therapy for Arm E before PBSC infusion/ASCT; administered intravenously.

    Also known as: L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin, Evomela

  • Supplied by Regeneron; used in Arm F consolidation for 8 cycles before maintenance therapy.

    Also known as: REGN5458

  • DeviceOn Body Delivery System (OBDS)

    Device: On Body Delivery System (OBDS) - Sanofi-Aventis device used with isatuximab administration; abdominal/periumbilical single-site application with post-dose needle retraction and lock-out.

    Also known as: Isatuximab SC Wearable Injection System

06

What researchers measure

Primary outcomes

  1. 3-Year Sustained Minimal Residual Disease (sMRD)-negative Complete Response (CR) Rate [Cohort 1] (Step 2)

    sMRD-negative CR rate is defined as the proportion of participants who sustain MRD negativity at a minimum 10\^-5 sensitivity assessed by next-generation sequencing (NGS) during the time of confirmed CR or better response per the International Myeloma Working Group Uniform Response Criteria (IMWG-URC).

    Time frame: Assessed after Step 2 maintenance cycle 36 (cycle duration=4 weeks), at 144 weeks/36 months.

  2. 1-Year MRD-Negative CR Rate [Cohort 2] (Step 2)

    MRD-negative CR rate is defined as the proportion of participants who achieve MRD negativity at a minimum 10\^-5 sensitivity assessed by NGS during the time of confirmed CR or better response per IMWG-URC.

    Time frame: Assessed 1-year after Step 2 consolidation randomization.

Secondary outcomes

  1. 1-Year MRD-Negative CR Rate [Cohort 1] (Step 3)

    MRD-negative CR rate is defined as the proportion of participants who sustain MRD negativity or convert to MRD negativity at a minimum 10\^-5 sensitivity assessed by NGS during the time of confirmed CR or better response per IMWG-URC.

    Time frame: Assessed after Step 3 maintenance cycle 12 (cycle duration=4 weeks), at 48 weeks/12 months.

  2. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Role Functioning (RF) Subscale Response [Cohort 1] (Step 2)

    EORTC QLQ-C30 RF subscale response is defined as an increase of ≥15 points in the RF score from Step 2 baseline, based on established guidelines. The RF subscale consists of 2 items scored on a 4-point Likert scale ("Not at all" to "Very much"). Raw scores are reverse scored and linearly transformed to a 0-100 scale then averaged, with higher scores indicating better functioning. Number of responses over Step 2 maintenance treatment is summed by participant.

    Time frame: Assessed day 1 every 3 cycles during Step 2 maintenance cycles 1-36 (cycle duration=4 weeks), up to 144 weeks/36 months.

  3. EORTC QLQ-C30 RF Subscale Response [Cohort 1] (Step 3)

    EORTC QLQ-C30 RF subscale response is defined as an increase of ≥15 points in the RF score from Step 3 baseline, based on established guidelines. The RF subscale consists of 2 items scored on a 4-point Likert scale ("Not at all" to "Very much"). Raw scores are reverse scored and linearly transformed to a 0-100 scale then averaged, with higher scores indicating better functioning. Number of responses over Step 3 maintenance treatment is summed by participant.

    Time frame: Assessed day 1 every 2 cycles during Step 3 maintenance cycles 1-12 (cycle duration=4 weeks), up to 48 weeks/12 months.

  4. Median Progression-Free Survival (PFS) [Cohort 1] (Step 2)

    PFS based on Kaplan-Meier method is defined as the time from maintenance Step 2 registration until the earlier of disease progression (PD) per IMWG-URC or death due to any cause (events). Deaths occurring beyond 6 months from the date last known progression-free are not counted as events and instead censored at the date of last disease evaluation. Patients who start Non-Protocol Therapy (NPT) prior to PD are censored at the date of NPT. Patients alive who did not experience PD or start NPT are censored at the date of last disease evaluation.

    Time frame: Assessed day 1 of each cycle during Step 2 maintenance cycles 1-36 (cycle duration=4 weeks) on treatment, up to 144 weeks/36 months. In long-term follow-up, assessed every 3 months, up to 88 months after Step 2 maintenance registration.

  5. Median Progression-Free Survival (PFS) [Cohort 1] (Step 3)

    PFS based on Kaplan-Meier method is defined as the time from maintenance Step 3 registration until the earlier of PD per IMWG-URC or death due to any cause (events). Deaths occurring beyond 6 months from the date last known progression-free are not counted as events and instead censored at the date of last disease evaluation. Patients who start NPT prior to PD are censored at the date of NPT. Patients alive who did not experience PD or start NPT are censored at the date of last disease evaluation.

    Time frame: Assessed day 1 of each cycle during Step 3 maintenance cycle 1 and beyond (cycle duration=4 weeks) on treatment. In long-term follow-up, assessed every 3 months, up to 52 months after Step 3 registration.

  6. Best Response [Cohort 1] (Step 2)

    Frequency of best response over Step 2 maintenance including stringent complete response(sCR), CR, very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease (SD) or progressive disease (PD) per IMWG-URC.

    Time frame: Assessed at day 1 of each cycle over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months.

  7. Best Response [Cohort 1] (Step 3)

    Frequency of best response over Step 3 maintenance including sCR, CR, VGPR, PR, MR, SD or PD per IMWG-URC.

    Time frame: Assessed day 1 of every cycle of Step 3 maintenance treatment and in long term follow-up every 3 months, up to approximately 52 months.

  8. Serious Adverse Events (SAE) Rate [Cohort 1] (Step 2)

    SAE rate is defined as the proportion of participants who experience any untoward medical occurrence at any dose that results in death, is life-threatening (i.e., the patient was at risk of death at the time of the event, not hypothetically), requires inpatient hospitalization or prolongation of existing hospitalization (excluding planned hospitalizations), results in persistent or significant disability or incapacity (defined as substantial disruption of normal life functions), is a congenital anomaly or birth defect, or is considered a medically important event.

    Time frame: Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.

  9. SAE Rate [Cohort 1] (Step 3)

    SAE rate is defined as the proportion of participants who experience any untoward medical occurrence at any dose that results in death, is life-threatening (i.e., the patient was at risk of death at the time of the event, not hypothetically), requires inpatient hospitalization or prolongation of existing hospitalization (excluding planned hospitalizations), results in persistent or significant disability or incapacity (defined as substantial disruption of normal life functions), is a congenital anomaly or birth defect, or is considered a medically important event.

    Time frame: Assessed continuously over Step 2 maintenance treatment (cycle duration=4 weeks), up to approximately 52 months + 30 days.

  10. Grade 3 or Higher Non-Hematologic (NH) Treatment-Related Adverse Event (TRAE) Rate [Cohort 1] (Step 2)

    Grade 3 or higher NH TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 maintenance therapy.

    Time frame: Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.

  11. 1-Year Grade 3 or Higher Hematologic TRAE Rate [Cohort 1] (Step 3)

    Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 3 maintenance therapy.

    Time frame: Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.

  12. Grade 3 or Higher TRAE Rate [Cohort 1] (Step 2)

    Grade 3 or higher TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic or non-hematologic adverse event based on CTCAEv5 with a treatment attribution of possible, probable or definite over maintenance therapy.

    Time frame: Assessed continuously over 36 cycles of Step 2 maintenance treatment (cycle duration=4 weeks), up to 144 weeks/36 months + 30 days.

  13. 1-Year Grade 3 or Higher Non-Hematologic (NH) Treatment-Related Adverse Event (TRAE) Rate [Cohort 1] (Step 3)

    Grade 3 or higher NH TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 3 maintenance therapy.

    Time frame: Assessed continuously over 12 cycles of Step 3 maintenance (cycle duration=4 weeks), up to 1 year + 30 days.

  14. 1-Year Grade 3 or Higher Hematologic TRAE Rate [Cohort 1] (Step 3)

    Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 3 maintenance therapy.

    Time frame: Assessed continuously over 12 cycles of Step 3 maintenance (cycle duration=4 weeks), up to 1 year + 30 days.

  15. 1-Year Grade 3 or Higher TRAE Rate [Cohort 1] (Step 3)

    Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH or hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 3 maintenance therapy.

    Time frame: Assessed continuously over 12 cycles of Step 3 maintenance (cycle duration=4 weeks), up to 1 year + 30 days.

  16. 1-Year EORTC QLQ-C30 RF Subscale Response [Cohort 2] (Step 2)

    EORTC QLQ-C30 RF subscale response is defined as an increase of ≥15 points in the RF score from Step 2 baseline, based on established guidelines. The RF subscale consists of 2 items scored on a 4-point Likert scale ("Not at all" to "Very much"). Raw scores are reverse scored and linearly transformed to a 0-100 scale then averaged, with higher scores indicating better functioning. Number of responses over Step 2 consolidation and maintenance treatment, up to 1 year, are summed by participant.

    Time frame: Assessed day 1 every 2 cycles or every 2 months on Step 2 treatment, up to 1 year.

  17. Median PFS [Cohort 2] (Step 2)

    PFS based on Kaplan-Meier method is defined as the time from Step 2 randomization until the earlier of PD per IMWG-URC or death due to any cause (events). Deaths occurring beyond 6 months from the date last known progression-free are not counted as events and instead censored at the date of last disease evaluation. Patients who start NPT prior to PD are censored at the date of NPT. Patients alive who did not experience PD or start NPT are censored at the date of last disease evaluation.

    Time frame: Assessed day 1 of each cycle or every month during Step 2 treatment. In long-term follow-up, assessed every 3 months, up to 88 months after Step 2 randomization.

  18. Maintenance Best Response [Cohort 2] (Step 2)

    Frequency of best response over Step 2 maintenance including sCR, CR, VGPR, PR, MR, SD or PD per IMWG-URC.

    Time frame: Assessed at day 1 of each cycle over Step 2 maintenance treatment (cycle duration=4 weeks), up to 80 months.

  19. 1-Year Best Response [Cohort 2] (Step 2)

    Frequency of best response over Step 2 consolidation and maintenance treatment up, to 1-year, including sCR, CR, VGPR, PR, MR, SD or PD per IMWG-URC.

    Time frame: Assessed at day 1 of each cycle or every month over Step 2 treatment, up to 1 year.

  20. Consolidation Best Response [Cohort 2] (Step 2)

    Frequency of best response over Step 2 consolidation treatment up including sCR, CR, VGPR, PR, MR, SD or PD per IMWG-URC.

    Time frame: Assessed day 1 over 8 cycles of Step 2 consolidation (cycle duration=4 weeks), up to 32 weeks/8 months; or from start of high-dose melphalan (HDM) day -2, though day 0 peripheral blood stem cell (PBSC) infusion up to maintenance start prior to day 110.

  21. Maintenance SAE Rate [Cohort 2] (Step 2)

    SAE rate is defined as the proportion of participants who experience any untoward medical occurrence at any dose that results in death, is life-threatening (i.e., the patient was at risk of death at the time of the event, not hypothetically), requires inpatient hospitalization or prolongation of existing hospitalization (excluding planned hospitalizations), results in persistent or significant disability or incapacity (defined as substantial disruption of normal life functions), is a congenital anomaly or birth defect, or is considered a medically important event over Step 2 maintenance treatment.

    Time frame: Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.

  22. Consolidation SAE Rate [Cohort 2] (Step 2)

    SAE rate is defined as the proportion of participants who experience any untoward medical occurrence at any dose that results in death, is life-threatening (i.e., the patient was at risk of death at the time of the event, not hypothetically), requires inpatient hospitalization or prolongation of existing hospitalization (excluding planned hospitalizations), results in persistent or significant disability or incapacity (defined as substantial disruption of normal life functions), is a congenital anomaly or birth defect, or is considered a medically important event over Step 2 consolidation.

    Time frame: Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.

  23. Maintenance Grade 3 or Higher NH TRAE Rate [Cohort 2] (Step 2)

    Grade 3 or higher NH TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 maintenance therapy.

    Time frame: Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.

  24. 1-Year Grade 3 or Higher NH TRAE Rate [Cohort 2] (Step 2)

    Grade 3 or higher NH TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation and maintenance therapy, up to 1-year.

    Time frame: Assessed continuously over Step 2 consolidation and maintenance treatment, up to 1-year + 30 days.

  25. Maintenance Grade 3 or Higher Hematologic TRAE Rate [Cohort 2] (Step 2)

    Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 maintenance therapy.

    Time frame: Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.

  26. 1-Year Grade 3 or Higher Hematologic TRAE Rate [Cohort 2] (Step 2)

    Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation and maintenance therapy, up to 1- year + 30 days.

    Time frame: Assessed continuously over Step 2 consolidation and maintenance treatment, up to 1-year + 30 days.

  27. Maintenance Grade 3 or Higher TRAE Rate [Cohort 2] (Step 2)

    Grade 3 or higher TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic or NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 maintenance therapy.

    Time frame: Assessed continuously over Step 2 maintenance treatment, up to 80 months + 30 days.

  28. 1-Year Grade 3 or Higher TRAE Rate [Cohort 2] (Step 2)

    Grade 3 or higher TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic or NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation and maintenance therapy, up to 1-year + 30 days.

    Time frame: Assessed continuously over Step 2 consolidation and maintenance treatment, up to 1-year + 30 days.

  29. Consolidation Grade 3 or Higher NH TRAE Rate [Cohort 2] (Step 2)

    Grade 3 or higher NH TRAE rate is defined as the proportion of participants who experience a grade 3 or higher NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation.

    Time frame: Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.

  30. Consolidation Grade 3 or Higher Hematologic TRAE Rate [Cohort 2] (Step 2)

    Grade 3 or higher hematologic TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation.

    Time frame: Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.

  31. Consolidation Grade 3 or Higher TRAE Rate [Cohort 2] (Step 2)

    Grade 3 or higher TRAE rate is defined as the proportion of participants who experience a grade 3 or higher hematologic or NH AE based on CTCAEv5 with a treatment attribution of possible, probable or definite over Step 2 consolidation.

    Time frame: Assessed continuously over 8 Step 2 consolidation cycles (4 weeks each), up to 32 weeks/8 months +30 days; or from high-dose melphalan (HDM) day -2 through day 0 PBSC infusion to maintenance start before day 110 +30 days.

07

Study locations

1 of 3 sites recruiting
08

References and documents

Publications

  • Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015 Mar 26;125(13):2068-74. doi: 10.1182/blood-2014-12-615187. Epub 2015 Jan 27. PubMed 25628469 ↗
  • Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva B, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Prosper F, Munshi NC. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025 Aug 20;43(24):2739-2751. doi: 10.1200/JCO-24-01893. Epub 2025 Jun 9. PubMed 40489728 ↗
  • Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. PubMed 27511158 ↗
  • Cocks K, Buchanan J. How scoring limits the usability of minimal important differences (MIDs) as responder definition (RD): an exemplary demonstration using EORTC QLQ-C30 subscales. Qual Life Res. 2023 May;32(5):1247-1253. doi: 10.1007/s11136-022-03181-4. Epub 2022 Jul 9. PubMed 35809136 ↗

Individual participant data

Plan to share: Yes — The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2033, 85 months after the start.

Of 72 non-industry phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 108. This study's planned 85 months is close to that.

Counting every sponsor, half of 181 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2026
First posted
Jun 3, 2026
StartActual
Aug 31, 2026
Primary completionEst.
Oct 1, 2033
CompletionEst.
Mar 1, 2038
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
Show 3 sites
  • Beth Israel Deaconess Medical Center (BIDMC) · Boston, United Statesno status→Not yet recruiting
  • Brigham and Women's Hospital · Boston, United Statesno status→Not yet recruiting
  • Dana-Farber Cancer Institute · Boston, United Statesno status→Recruiting
Oct 9, 2026
Start date
Aug 24, 2026→Aug 31, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    3 sites changed recruiting status (2 now not yet recruiting, 1 now recruiting)
    Show 3 sites
    • Beth Israel Deaconess Medical Center (BIDMC) · Boston, United Statesno status→Not yet recruiting
    • Brigham and Women's Hospital · Boston, United Statesno status→Not yet recruiting
    • Dana-Farber Cancer Institute · Boston, United Statesno status→Recruiting
    Start date Aug 24, 2026→Aug 31, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07624513
Responsible party
Clifton Mo, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Jun 3, 2026
Start date
Aug 31, 2026
Primary completion
Oct 1, 2033 (estimated)
Completion
Mar 1, 2038 (estimated)
Last update
Oct 9, 2026

Study contacts

Clifton C. Mo, MD
Contact
Clifton_Mo@dfci.harvard.edu
617-582-7969
Clifton C. Mo, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isatuximab

Start the discussion